The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
Open accessAbstract
This article provides a comprehensive review of currently available treatment options for infections due to carbapenem-resistant Enterobacteriaceae (CRE). Antimicrobial resistance in Gram-negative bacteria is an emerging and serious global public health threat. Carbapenems have been used as the “last-line” treatment for infections caused by resistant Enterobacteriaceae, including those producing extended spectrum ß-lactamases. However, Enterobacteriaceae that produce carbapenemases, which are enzymes that deactivate carbapenems and most other ß-lactam antibiotics, have emerged and are increasingly being reported worldwide. Despite this increasing burden, the most optimal treatment for CRE infections is largely unknown. For the few remaining available treatment options, there are limited efficacy data to support their role in therapy. Nevertheless, current treatment options include the use of older agents, such as polymyxins, fosfomycin, and aminoglycosides, which have been rarely used due to efficacy and/or toxicity concerns. Optimization of dosing regimens and combination therapy are additional treatment strategies being explored. Carbapenem-resistant Enterobacteriaceae infections are associated with poor outcomes and high mortality. Continued research is critically needed to determine the most appropriate treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Carbapenem resistance in Enterobacteriaceae: here is the storm!
Nordmann, P., Dortet, L., & Poirel, L. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.03.003 · Cited by 1,038
Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
OXA-48-like carbapenemases: the phantom menace
Poirel, L., Potron, A., & Nordmann, P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks121 · Cited by 924
Garonzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02166-13 · Cited by 597
Qureshi, Z. A., Paterson, D. L., Potoski, B. A., Kilayko, M. C., Sandovsky, G., Sordillo, E., Polsky, B., Adams-Haduch, J. M., & Doi, Y. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06268-11 · Cited by 559
Vital signs: carbapenem-resistant Enterobacteriaceae.
(2013) · PubMed Central · Cited by 531
Falagas, M. E., Kastoris, A. C., Kapaskelis, A. M., & Karageorgopoulos, D. E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70325-1 · Cited by 487
Hirsch, E. B., & Tam, V. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq108 · Cited by 477
Zarkotou, O., Pournaras, S., Tselioti, P., Dragoumanos, V., Pitiriga, V., Ranellou, K., Prekates, A., Themeli-Digalaki, K., & Tsakris, A. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03514.x · Cited by 438
Sandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., Behle, T. F., Bordinhão, R. C., Wang, J., Forrest, A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit334 · Cited by 430
Falagas, M. E., Lourida, P., Poulikakos, P., Rafailidis, P. I., & Tansarli, G. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01222-13 · Cited by 351
Roberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347
Livermore, D. M., Warner, M., Mushtaq, S., Doumith, M., Zhang, J., & Woodford, N. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.01.012 · Cited by 341
Treating infections caused by carbapenemase-producing Enterobacteriaceae
Tzouvelekis, L. S., Markogiannakis, A., Piperaki, E., Souli, M., & Daikos, G. L. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12697 · Cited by 337
Gales, A. C., Jones, R. N., & Sader, H. S. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr239 · Cited by 337
Pogue, J. M., Lee, J., Marchaim, D., Yee, V., Zhao, J. J., Chopra, T., Lephart, P., & Kaye, K. S. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir611 · Cited by 327
Self-citationBratu, S., Tolaney, P., Karumudi, U., Quale, J., Mooty, M., Nichani, S., & Landman, D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki175 · Cited by 307
Falagas, M. E., Rafailidis, P. I., Ioannidou, E., Alexiou, V. G., Matthaiou, D. K., Karageorgopoulos, D. E., Kapaskelis, A., Nikita, D., & Michalopoulos, A. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.005 · Cited by 300
Antoniadou, A., Kontopidou, F., Poulakou, G., Koratzanis, E., Galani, I., Papadomichelakis, E., Kopterides, P., Souli, M., Armaganidis, A., & Giamarellou, H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl562 · Cited by 273
Souli, M., Galani, I., Antoniadou, A., Papadomichelakis, E., Poulakou, G., Panagea, T., Vourli, S., Zerva, L., Armaganidis, A., Kanellakopoulou, K., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649865 · Cited by 271
Leavitt, A., Navon-Venezia, S., Chmelnitsky, I., Schwaber, M. J., & Carmeli, Y. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00299-07 · Cited by 256
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
Peleg, A. Y., Potoski, B. A., Rea, R., Adams, J., Sethi, J., Capitano, B., Husain, S., Kwak, E. J., Bhat, S. V., & Paterson, D. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl441 · Cited by 248
De Pascale, G., Montini, L., Pennisi, M. A., Bernini, V., Maviglia, R., Bello, G., Spanu, T., Tumbarello, M., & Antonelli, M. (2014) · Critical Care · doi:10.1186/cc13858 · Cited by 245
Daikos, G. L., & Markogiannakis, A. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03553.x · Cited by 238
Lucasti, C., Popescu, I., Ramesh, M. K., Lipka, J., & Sable, C. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks523 · Cited by 234
Carbapenem‐resistant Enterobacteriaceae: biology, epidemiology, and management
Temkin, E., Adler, A., Lerner, A., & Carmeli, Y. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12537 · Cited by 223
Vazquez, J. A., González Patzán, L. D., Stricklin, D., Duttaroy, D. D., Kreidly, Z., Lipka, J., & Sable, C. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.748653 · Cited by 219
Anthony, K. B., Fishman, N. O., Linkin, D. R., Gasink, L. B., Edelstein, P. H., & Lautenbach, E. (2008) · Clinical Infectious Diseases · doi:10.1086/526775 · Cited by 210
Combination therapy for carbapenem-resistant Gram-negative bacteria
Paul, M., Carmeli, Y., Durante-Mangoni, E., Mouton, J. W., Tacconelli, E., Theuretzbacher, U., Mussini, C., & Leibovici, L. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku168 · Cited by 210
Marchaim, D., Chopra, T., Pogue, J. M., Perez, F., Hujer, A. M., Rudin, S., Endimiani, A., Navon-Venezia, S., Hothi, J., Slim, J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-10 · Cited by 208
Self-citationAkova, M., Daikos, G. L., Tzouvelekis, L., & Carmeli, Y. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03823.x · Cited by 205
Dudhani, R. V., Turnidge, J. D., Coulthard, K., Milne, R. W., Rayner, C. R., Li, J., & Nation, R. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01114-09 · Cited by 205
Akajagbor, D. S., Wilson, S. L., Shere-Wolfe, K. D., Dakum, P., Charurat, M. E., & Gilliam, B. L. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit453 · Cited by 205
Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
Bulik, C. C., & Nicolau, D. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01420-10 · Cited by 200
Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem
Kuti, J. L., Dandekar, P. K., Nightingale, C. H., & Nicolau, D. P. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003257225 · Cited by 199
Lee, G. C., & Burgess, D. S. (2012) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-11-32 · Cited by 199
Fosfomycin: an old, new friend?
Popovic, M., Steinort, D., Pillai, S., & Joukhadar, C. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0833-2 · Cited by 197
Peleg, A. Y., Franklin, C., Bell, J. M., & Spelman, D. W. (2005) · Clinical Infectious Diseases · doi:10.1086/497831 · Cited by 190
Perry, J. D., Naqvi, S. H., Mirza, I. A., Alizai, S. A., Hussain, A., Ghirardi, S., Orenga, S., Wilkinson, K., Woodford, N., Zhang, J., et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr299 · Cited by 188
Dudhani, R. V., Turnidge, J. D., Nation, R. L., & Li, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq226 · Cited by 181
Inhibitor Resistance in the KPC-2 β-Lactamase, a Preeminent Property of This Class A β-Lactamase
Papp-Wallace, K. M., Bethel, C. R., Distler, A. M., Kasuboski, C., Taracila, M., & Bonomo, R. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00693-09 · Cited by 180
Phe, K., Lee, Y., McDaneld, P. M., Prasad, N., Yin, T., Figueroa, D. A., Musick, W. L., Cottreau, J. M., Hu, M., & Tam, V. H. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02476-13 · Cited by 180
Castanheira, M., Farrell, S. E., Krause, K. M., Jones, R. N., & Sader, H. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01896-13 · Cited by 177
Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients
Li, C., Kuti, J. L., Nightingale, C. H., & Nicolau, D. P. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291035 · Cited by 171
Aktaş, Z., Kayacan, C., & Oncul, O. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.09.012 · Cited by 169
Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new?
Bergen, P. J., Landersdorfer, C. B., Zhang, J., Zhao, M., Lee, H. J., Nation, R. L., & Li, J. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.07.010 · Cited by 162
Treatment of carbapenem-resistantKlebsiella pneumoniae: the state of the art
Petrosillo, N., Giannella, M., Lewis, R. E., & Viale, P. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.162 · Cited by 156
Combination therapy for carbapenem-resistant Gram-negative bacteria
Zavascki, A. P., Bulitta, J. B., & Landersdorfer, C. B. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.845523 · Cited by 144
Satlin, M. J., Kubin, C. J., Blumenthal, J. S., Cohen, A. B., Furuya, E. Y., Wilson, S. J., Jenkins, S. G., & Calfee, D. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00387-11 · Cited by 132
Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge
Francisco, C. N.-S., Mora-Rillo, M., Romero‐Gómez, M. P., Moreno-Ramos, F., Rico-Nieto, A., Carrascoso, G. R., Gómez-Gil, R., Arribas, J. R., Mingorance, J., & Paño‐Pardo, J. R. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12091 · Cited by 130
Lynch, J. P., Clark, N. M., & Zhanel, G. G. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.763030 · Cited by 126
Giamarellou, H., Galani, L., Baziaka, F., & Karaiskos, I. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02399-12 · Cited by 125
Bratu, S., Brooks, S., Burney, S. N., Kochar, S., Gupta, J., Landman, D., & Quale, J. M. (2007) · Clinical Infectious Diseases · doi:10.1086/512370 · Cited by 122
Balkan, İ. İ., Aygün, G., Aydın, S., Mutcalı, S. I., Kara, Z., Kuşkucu, M. A., Midilli, K., Şemen, V., Aras, Ş., Yemişen, M., et al. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.05.012 · Cited by 112
Lee, J., Patel, G., Huprikar, S. S., Calfee, D. P., & Jenkins, S. G. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.02466-08 · Cited by 110
Plasmid-Mediated Carbapenem-Hydrolyzing Enzyme KPC-2 in an Enterobacter sp
Hossain, A., Ferraro, M. J., Pino, R. M., Dew, R. B., Moland, E. S., Lockhart, T. J., Thomson, K. S., Goering, R. V., & Hanson, N. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4438-4440.2004 · Cited by 108
Nguyen, M. T., Eschenauer, G. A., Bryan, M. K., O’Neil, K. A., Furuya, E. Y., Della‐Latta, P., & Kubin, C. J. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.02.001 · Cited by 108
Vicari, G., Bauer, S. R., Neuner, E. A., & Lam, S. W. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis909 · Cited by 107
Sbrana, F., Malacarne, P., Viaggi, B., Costanzo, S., Léonetti, P., Leonildi, A., Casini, B., Tascini, C., & Menichetti, F. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis969 · Cited by 100
Optimization of Aminoglycoside Therapy
Drusano, G. L., & Louie, A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01314-10 · Cited by 92
Ceccarelli, G., Falcone, M., Giordano, A., Mezzatesta, M. L., Caio, C., Stefani, S., & Venditti, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00188-13 · Cited by 88
Daikos, G. L., Markogiannakis, A., Souli, M., & TZOUVELEKIS, L. S. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.138 · Cited by 66
Karageorgopoulos, D. E., Miriagou, V., TZOUVELEKIS, L. S., Spyridopoulou, K., & Daikos, G. L. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks270 · Cited by 60
Antimicrobial Susceptibility Patterns of KPC-Producing or CTX-M-Producing Enterobacteriaceae
Castanheira, M., Sader, H. S., & Jones, R. N. (2010) · Microbial Drug Resistance · doi:10.1089/mdr.2009.0031 · Cited by 51
Sader, H. S., Farrell, D. J., Flamm, R. K., & Jones, R. N. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02684-13 · Cited by 47
Cited by
Carbapenem resistance: overview of the problem and future perspectives
Meletis, G. (2016) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936115621709 · Cited by 725
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings
Wu, W., Feng, Y., Tang, G., Qiao, F., McNally, A., & Zong, Z. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-18 · Cited by 700
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
Shields, R. K., Chen, L., Cheng, S., Chavda, K. D., Press, E. G., Snyder, A., Pandey, R., Doi, Y., Kreiswirth, B. N., Nguyen, M. H., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02097-16 · Cited by 484
Metadata
- Authors
- Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L.
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015
- Volume
- 2
- Issue
- 2
- Pages
- ofv050-ofv050
- ISSN
- 2328-8957 (ISSN-L)
- OpenAlex
- W2112203749
- Cited by
- 435
- References
- 67
- FWCI
- 16.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.